Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
Chiuppesi F, Zaia J, Frankel P, Stan R, Drake J, Williams B, Acosta A, Francis K, Taplitz R, Dickter J, Dadwal S, Puing A, Nanayakkara D, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen V, Francisco S, Grifoni A, Wong A, Sette A, Wussow F, Diamond D. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. The Lancet Microbe 2022, 3: e252-e264. PMID: 35287430, PMCID: PMC8906816, DOI: 10.1016/s2666-5247(22)00027-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, ViralCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedSARS-CoV-2Vaccinia virusYoung AdultConceptsPhase 1 trialVaccinia virus AnkaraPlacebo vaccineVirus AnkaraExact testDay 0SARS-CoV-2 antibodiesCOVID-19 vaccine candidatesHope Comprehensive Cancer CenterDose-expansion cohortsGrade 3 feverOpen-label cohortSevere adverse eventsAdditional secondary outcomesModified vaccinia virus AnkaraT cell responsesBody mass indexNegative pregnancy testComprehensive cancer centerSARS-CoV-2 spikeNucleocapsid-specific antibodiesFisher's exact testCOVID-19 vaccineSARS-CoV-2Plaque-forming units